William Pearce, MD
Urology · Orange, CANPI 1730293838
Payments from drug & device makers
Across 215 payments — averaging $40.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Teleflex LLC$1K
- Procept Biorobotics Corporation$916
- Boston Scientific$902
- Coloplast$869
- Biotissue Holdings Inc.$390
- plus $3K from 29 others
What the payments were for
- Travel & lodging$98511%
- Food & beverage$6,14871%
- Education$1,56318%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $1,895 |
| Teleflex LLC | 46 | $1,137 |
| Procept Biorobotics Corporation | 16 | $916 |
| Boston Scientific | 26 | $902 |
| Coloplast | 17 | $869 |
| Biotissue Holdings Inc. | 11 | $390 |
| Urogen Pharma, Inc. | 10 | $379 |
| Neotract Inc. | 18 | $378 |
| Agiliti Surgical, Inc. | 2 | $235 |
| Sumitomo Pharma America, Inc. | 10 | $203 |
| Astellas Pharma US Inc | 9 | $189 |
| Mimedx Group, Inc. | 2 | $145 |
| Myovant Sciences Inc. | 7 | $128 |
| AbbVie | 3 | $92 |
| BD | 1 | $86 |
| Baxter Healthcare | 2 | $82 |
| Immunitybio, Inc. | 3 | $66 |
| Medtronic | 1 | $63 |
| Olympus America Inc. | 3 | $60 |
| Laborie Medical Technologies Corp. | 3 | $50 |
| Bayer | 2 | $46 |
| ABC Home Medical Supply, Inc. | 2 | $40 |
| Urovant Sciences Inc | 2 | $40 |
| Integra Lifesciences Corporation | 1 | $36 |
| Bioprotect Medical, Inc. | 1 | $35 |
| Photocure Inc | 2 | $32 |
| Davol Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Shionogi Inc | 1 | $25 |
| Novartis | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Blue Earth Diagnostics | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$1,500
- AquaBeam Robotic System$502
- Da Vinci Surgical System$352
- Saffron$213
- ALTIS$177
- AMS 700$146
- Sonablate HIFU$137
- UroLift$135
- NEOX$128
- CLARIX$128
How this compares
$8,695 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 114 | $104,582 |
| GemtesaVibegron | 17 | $13,417 |
| Tamsulosin Hcl | 385 | $5,356 |
| Solifenacin Succinate | 72 | $4,642 |
| NitrofurantoinNitrofurantoin Macrocrystal | 77 | $3,886 |
| Oxybutynin Chloride ErOxybutynin Chloride | 139 | $3,733 |
| Desmopressin Acetate | 27 | $3,683 |
| Tolterodine Tartrate ErTolterodine Tartrate | 27 | $3,361 |
| Estradiol | 35 | $2,476 |
| Finasteride | 134 | $2,147 |
| Terazosin Hcl | 88 | $1,263 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 60 | $1,068 |
| Sildenafil Citrate | 60 | $992 |
| Ciprofloxacin Hcl | 174 | $925 |
| Oxybutynin Chloride | 59 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $189 | $104,582114 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $203 | $13,41717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,324 urology providers in California.
Other urology in Orange
- Edward UchioOrange$21.1M
- Ralph ClaymanOrange$3.9M
- Jaime LandmanOrange$851K
- Faysal YafiOrange$346K
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.